v3.23.1
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Current assets:    
Cash $ 1,412 $ 357
Accounts receivable 17 9
Inventory, short term 345 336
Net investment in leases, short term 101 101
Prepaid expenses and vendor deposits4 275 325
Total current assets 2,150 1,128
Property and equipment, net 630 665
Right-to-use assets, net 634 705
Other assets:    
Inventory, long term 1,142 1,141
Net investment in leases, long term 94 120
Patents, net 303 307
Other assets 244 44
Total assets 5,197 4,110
Current liabilities:    
Accounts payable and accrued expenses, including $0 and $120 to related parties as of March 31, 2023 and December 31, 2022, respectively 2,392 2,852
Customer deposits 8 0
Deferred revenue, short term 0 5
Dividends payable 93 91
Lease liability, short term 321 313
Total current liabilities 2,814 3,261
Lease liability, long term 368 452
Total long-term liabilities 368 452
Total liabilities 3,182 3,713
Convertible Preferred Stock 105 105
Equity:    
Preferred stock 0 0
Common stock, $0.001 par value, authorized 200,000,000 shares, 66,857,687 and 54,610,638 issued and outstanding as of March 31, 2023 and December 31, 2022, respectively 67 55
Additional paid in capital 225,215 216,232
Accumulated deficit (223,306) (215,974)
Total stockholders' equity attributable to BioSig Technologies, Inc. 1,976 313
Non-controlling interest (66) (21)
Total equity 1,910 292
Total liabilities and equity $ 5,197 $ 4,110

Source

PDF HTML
10-Q Filing
ZIP XLS
XBRL